BMJ:结肠镜阴性人群后继肿瘤风险研究

2019-11-15 MedSci MedSci原创

研究发现,对于结肠镜检查阴性人群,20%的参与者5年内会发生肿瘤,但10年内晚期肿瘤的发病率较低,因此结肠镜阴性人群间隔10年进行二次筛查是足够的

近日研究人考察了结直肠腺瘤阴性人群随后结肠镜筛查的结果,并按检查间隔和性别进行分层。

本次研究为系统综述及荟萃分析研究,评估在既往结肠镜检查中结肠直肠癌平均风险参与者(无腺瘤)随后的结肠镜检查结果。

28项研究,包括22项队列研究、5项横断面研究和1例病例对照研究。17、16和3项研究分别报告了1-5年、5-10年和10年以上结肠镜检查的结果。在结肠镜检查后1-5年、5-10年和10年以上,任何肿瘤的总患病率分别为20.7%、23.0%和21.9%(14.9%-29.0%)。相应的晚期肿瘤发生率分别为2.8%、3.2%和7.0%,男性的发病率高于女性。

研究发现,对于结肠镜检查阴性人群,20%的参与者5年内会发生肿瘤,但10年内晚期肿瘤的发病率较低,因此首次结肠镜阴性人群间隔10年进行二次筛查是足够的。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1848891, encodeId=1781184889116, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Mar 21 10:01:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026045, encodeId=083520260454c, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Jun 23 21:01:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055687, encodeId=a0a2205568e2b, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jan 15 19:01:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434496, encodeId=06bd143449660, content=<a href='/topic/show?id=95de81e4889' target=_blank style='color:#2F92EE;'>#肠镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81748, encryptionId=95de81e4889, topicName=肠镜)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Nov 17 10:01:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375301, encodeId=32073e530160, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Nov 15 19:37:23 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2020-03-21 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1848891, encodeId=1781184889116, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Mar 21 10:01:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026045, encodeId=083520260454c, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Jun 23 21:01:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055687, encodeId=a0a2205568e2b, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jan 15 19:01:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434496, encodeId=06bd143449660, content=<a href='/topic/show?id=95de81e4889' target=_blank style='color:#2F92EE;'>#肠镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81748, encryptionId=95de81e4889, topicName=肠镜)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Nov 17 10:01:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375301, encodeId=32073e530160, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Nov 15 19:37:23 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1848891, encodeId=1781184889116, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Mar 21 10:01:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026045, encodeId=083520260454c, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Jun 23 21:01:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055687, encodeId=a0a2205568e2b, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jan 15 19:01:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434496, encodeId=06bd143449660, content=<a href='/topic/show?id=95de81e4889' target=_blank style='color:#2F92EE;'>#肠镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81748, encryptionId=95de81e4889, topicName=肠镜)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Nov 17 10:01:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375301, encodeId=32073e530160, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Nov 15 19:37:23 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1848891, encodeId=1781184889116, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Mar 21 10:01:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026045, encodeId=083520260454c, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Jun 23 21:01:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055687, encodeId=a0a2205568e2b, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jan 15 19:01:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434496, encodeId=06bd143449660, content=<a href='/topic/show?id=95de81e4889' target=_blank style='color:#2F92EE;'>#肠镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81748, encryptionId=95de81e4889, topicName=肠镜)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Nov 17 10:01:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375301, encodeId=32073e530160, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Nov 15 19:37:23 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-17 zhouqu_8
  5. [GetPortalCommentsPageByObjectIdResponse(id=1848891, encodeId=1781184889116, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Sat Mar 21 10:01:00 CST 2020, time=2020-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026045, encodeId=083520260454c, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Jun 23 21:01:00 CST 2020, time=2020-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055687, encodeId=a0a2205568e2b, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jan 15 19:01:00 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1434496, encodeId=06bd143449660, content=<a href='/topic/show?id=95de81e4889' target=_blank style='color:#2F92EE;'>#肠镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81748, encryptionId=95de81e4889, topicName=肠镜)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Nov 17 10:01:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375301, encodeId=32073e530160, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Fri Nov 15 19:37:23 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-15 一个字-牛

    学习了谢谢分享

    0

相关资讯

2019.V1版《NCCN结直肠癌诊治指南》更新要点解析

2019.V1 版《NCCN 结直肠癌诊治指南》与2018.V4 版《NCCN 结直肠癌诊治指南》相比,其做出了一些能改变临床实践的更新。本文就2019.V1 版《NCCN 结直肠癌诊治指南》中最为重要的几个更新要点进行了分析与解读,主要包括:(1)新增“BRAF 基因”作为指导治疗的一个指标;在所有标记“KRAS 野生型和NRAS 野生型”作为指征的地方,同时需标记“BRAF 野生型”;(2)“

JCO:结直肠癌患者坚持健身或能缓解病情

一项最新研究结果显示,如果转移性结直肠癌患者在接受化疗期间进行适度的体育锻炼,往往可以延缓病情的发展,化疗后的严重副作用也更少。

NCCN临床实践指南:遗传/家族高风险评估-结直肠癌(2019.V2)

2019年8月,美国国家综合癌症网络(NCCN)发布了结直肠癌遗传/家族高风险评估指南2019年第2版,指南更新摘要如下: 高风险结直肠癌综合征 非息肉病综合征 息肉病综合征

刚刚结束的ESMO会议,盘点下结直肠癌海报专场的8个研究!

笔者于9月27日至10月1日参加了在巴塞罗那举办的2019 ESMO年会。ESMO全名,European Society for Medical Oncology,即欧洲肿瘤内科学会。笔者去听了29号下午的结直肠癌海报专场报告的session,整理下这个专场的8个研究,和大家分享!这次海报汇报总共分享了8个主题,依次为:526PD- TRIUMPH研究:针对转移性结直肠癌伴肿瘤组织或循环肿瘤D

Brit J Cancer:Lynch综合征患者2型糖尿病、高胆固醇与结直肠癌风险增加有关

由此可见,对于Lynch综合征患者,自我报告的2型糖尿病和高胆固醇与结直肠癌的风险增加有关。

抗肿瘤药物处方审核专家共识——结直肠癌

为了进一步规范肿瘤的药物治疗,促进临床合理用药,改善结直肠癌患者的预后,由国家癌症中心、国家肿瘤质控中心药事质控专家委员会牵头,中国抗癌协会肿瘤临床药学专业委员会、中国药师协会肿瘤药师分会共同组织全国的药学专家,制定了《结直肠癌抗肿瘤药物处方审核专家共识》。 本共识首次提出运用“六步法”进行抗肿瘤药物处方审核: 即合法性审核-患者评估审核-方案审核-器官功能及实验室指标审核-预处理审核-非常规处方